Previous close | 2.3000 |
Open | 2.2000 |
Bid | 1.7000 |
Ask | 2.1500 |
Strike | 5.00 |
Expiry date | 2025-01-17 |
Day's range | 2.2000 - 2.3000 |
Contract range | N/A |
Volume | |
Open interest | 2.89k |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.